Diffuse Infiltrating Retinoblastoma with Anterior Chamber Involvement: Conservative Management and Identification of

Cell-free DNA Conservative treatment Diffuse infiltrating retinoblastoma Intracamerular chemotherapy Intravitreal chemotherapy Liquid biopsy RB1 mutation Retinoblastoma Retinoblastoma genetics

Journal

Ocular oncology and pathology
ISSN: 2296-4681
Titre abrégé: Ocul Oncol Pathol
Pays: Switzerland
ID NLM: 101656139

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 03 04 2023
accepted: 17 05 2023
medline: 30 10 2023
pubmed: 30 10 2023
entrez: 30 10 2023
Statut: ppublish

Résumé

The aim of the study was to describe the successful conservative management of diffuse infiltrating retinoblastoma (DIR). Identification of Herein, we report 2 patients with unilateral, non-familial DIR with anterior and posterior involvement. Both patients underwent liquid biopsy for tumor cfDNA analysis in aqueous humor. Treatment consisted of a combination of systemic and intra-arterial chemotherapy, with consecutive intracameral and intravitreal injections of melphalan. One patient also required iodine-125 brachytherapy. In both cases, tumor cfDNA analysis revealed biallelic somatic alterations of the In selected cases, conservative management of DIR is safe and effective. Tumor cfDNA analysis in aqueous humor is an effective technique to disclose

Identifiants

pubmed: 37900191
doi: 10.1159/000531233
pii: 531233
pmc: PMC10601847
doi:

Types de publication

Journal Article

Langues

eng

Pagination

96-100

Informations de copyright

© 2023 S. Karger AG, Basel.

Déclaration de conflit d'intérêts

The authors have no conflicts of interest to declare.

Références

Ocul Oncol Pathol. 2017 Jul;3(2):129-132
pubmed: 28868284
Ophthalmology. 2006 Dec;113(12):2276-80
pubmed: 16996605
J Mol Diagn. 2021 Dec;23(12):1714-1721
pubmed: 34656762
Ophthalmic Genet. 2016;37(1):95-7
pubmed: 24892564
Ophthalmic Genet. 2022 Dec;43(6):862-865
pubmed: 36326029
Ophthalmology. 2008 Dec;115(12):2253-8
pubmed: 18962920
Arch Pathol Lab Med. 2009 Aug;133(8):1215-8
pubmed: 19653712
Ocul Oncol Pathol. 2016 Apr;2(3):128-32
pubmed: 27239450
Retina. 2000;20(2):217-9
pubmed: 10783961
Br J Ophthalmol. 2019 Jun;103(6):826-830
pubmed: 30049803

Auteurs

Nathalie Cassoux (N)

Department of Ocular Oncology, Institut Curie, Paris, France.
Faculté de Médecine, Université Paris Cité, Paris, France.

Denis Malaise (D)

Department of Ocular Oncology, Institut Curie, Paris, France.

Livia Lumbroso-Le-Rouic (L)

Department of Ocular Oncology, Institut Curie, Paris, France.

Jessica Le Gall (J)

Department of Genetics, Institut Curie, Paris, France.

Lisa Golmard (L)

Department of Genetics, Institut Curie, Paris, France.

Liesbeth Cardoen (L)

Department of Radiology, Institut Curie, Paris, France.

Paul Freneaux (P)

Department of Pathology, Institut Curie, Paris, France.

Yassine Bouchoucha (Y)

Faculté de Médecine, Université Paris Cité, Paris, France.
SIREDO Oncology Center of Care, Innovation and Research for Children, Adolescent and Young Adults with Cancer, Institut Curie, Paris, France.

Isabelle Aerts (I)

SIREDO Oncology Center of Care, Innovation and Research for Children, Adolescent and Young Adults with Cancer, Institut Curie, Paris, France.

François Doz (F)

Faculté de Médecine, Université Paris Cité, Paris, France.
SIREDO Oncology Center of Care, Innovation and Research for Children, Adolescent and Young Adults with Cancer, Institut Curie, Paris, France.

Alexandre Matet (A)

Department of Ocular Oncology, Institut Curie, Paris, France.
Faculté de Médecine, Université Paris Cité, Paris, France.

Classifications MeSH